Oliver Kong

Oliver Kong has a wide range of experience in the medical field, starting as a Medical Oncologist at the Shanghai Cancer Hospital/Institute from 1987 to 1994. Oliver then worked as a Medical Affairs Manager at Schering-Plough Corporation from 1998 to 2000. Following that, they served as a Global Study Team Leader at Roche from 2001 to 2005, and as a Medical Director at Bayer from 2005 to 2007. From 2008 to 2015, they worked as a Senior Medical Director at Celgene, where they were responsible for designing and optimizing global phase III trials and leading the Clinical Development Team. Oliver then held the position of Senior Global Brand Medical Director at Novartis from 2015 to 2018. Most recently, they worked at Hengrui Therapeutics, Inc. as the Vice President of Clinical Oncology Development from 2018 to 2020. Currently, they are the Chief Medical Officer and Corporate Vice President at Qilu Pharmaceuticals.

Oliver Kong attended Roswell Park Cancer Institute from 1996 to 1998 as a Clinical Fellow with a focus on Cancer Immunotherapy. Oliver also studied at Fudan University, where they earned a Doctor of Medicine (MD) degree. In addition, they pursued a Master's degree in Molecular Immunology at the University of Nebraska Medical Center.